Genzyme rejects Sanofi's $18.5B offer

Sanofi-Aventis has finally gone public with its offer for Genzyme. But Genzyme announced its definite rejection of that bid; so the news is not just sources volleying in the media anymore. However, with no rival bidder in sight, it behooves Sanofi to drag out any eventual negotiations, analysts say. Report

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.